Progyny, Inc.
NASDAQ:PGNYMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $2.66B
- Beta
- 1.04
- P/E (TTM)
- 31.4
- EPS (TTM)
- $0.84
Volume 0.88M
Average 1.49M
PGNY EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Progyny, Inc.NASDAQ: PGNY
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) growth accelerates
Q2 FY2026 EPS (Diluted) of $0.34 rose 78.9% year over year, ahead of the +55.9% change in trailing-twelve-month EPS (Diluted). Sequentially, it rose 17.2% from the prior quarter. Over 3 fiscal years it compounded at +29.4% a year.
Context
- EPS (Diluted) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 6 analysts of $1.32 (+102.6%) for the fiscal year ending Dec 2026, a step up from the +14.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $0.34+17.2% QoQ
- Last fiscal yearDec 2025
- $0.65+14.0% YoY
- LTMJun 2026
- $0.92+55.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- 0.65 USD
- Year-over-year change
- +14.0%
- 4-year CAGR
- -0.4%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0.65 | +14.0% |
| FY2024 | 2024-12-31 | 0.57 | -8.1% |
| FY2023 | 2023-12-31 | 0.62 | +106.7% |
| FY2022 | 2022-12-31 | 0.30 | -54.5% |
| FY2021 | 2021-12-31 | 0.66 | — |
EPS (Diluted) vs competitors
How PGNY compares with its peers on the latest reported figures
- PGNY's LTM Jun 2026 EPS (Diluted) of $0.92 is the 2nd highest of the 3 companies compared; the peer median is $1.33.
- Its year-over-year change of +55.9% is the lowest of 3, against a peer median of +75.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jul 2026 | $2.77 | +67.4% | — | |
| LTM Jun 2026 | $0.92 | +55.9% | +29.4% | |
| LTM Mar 2026 | -$0.11 | +83.9% | — | |
| Peer median (excluding PGNY) | $1.33 | +75.7% | — | |
Competitors are the stored peer set for PGNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 500.62M | 786.91M | 1.09B | 1.17B | 1.29B |
| Cost of Revenue | 388.49M | 619.59M | 849.8M | 913.86M | 984.18M |
| Gross Profit | 112.14M | 167.33M | 238.8M | 253.36M | 304.48M |
| Gross Margin | 22.4% | 21.3% | 21.9% | 21.7% | 23.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 79.8M | 143.98M | 176.62M | 185.91M | 219.21M |
| Operating Expenses | 79.8M | 143.98M | 176.62M | 185.91M | 219.21M |
| Depreciation & Amortization | 1.3M | 1.6M | 2.28M | 3.18M | 4.95M |
| EBITDA | 33.74M | 26.04M | 72.97M | 86.38M | 100.38M |
| EBITDA Margin | 6.7% | 3.3% | 6.7% | 7.4% | 7.8% |
| Operating Income | 32.34M | 23.34M | 62.18M | 67.46M | 85.28M |
| Operating Margin | 6.5% | 3.0% | 5.7% | 5.8% | 6.6% |
| Interest Income | 461K | 814K | 8.51M | 15.75M | 10.16M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 95K | 1.1M | 8.51M | 15.75M | 10.16M |
| Income Before Tax | 32.44M | 24.44M | 70.69M | 83.2M | 95.43M |
| Pre-Tax Margin | 6.5% | 3.1% | 6.5% | 7.1% | 7.4% |
| Income Tax Expense | (33.33M) | (5.92M) | 8.65M | 28.87M | 36.91M |
| Net Income | 65.77M | 30.36M | 62.04M | 54.34M | 58.52M |
| Net Margin | 13.1% | 3.9% | 5.7% | 4.7% | 4.5% |
| EPS (Basic) | 0.74 | 0.33 | 0.65 | 0.59 | 0.68 |
| EPS (Diluted) | 0.66 | 0.30 | 0.62 | 0.57 | 0.65 |
| Weighted Avg Shares | 89.11M | 92.2M | 95.02M | 91.48M | 85.23M |
| Weighted Avg Shares (Diluted) | 100.36M | 99.96M | 100.67M | 95.45M | 89.46M |
Progyny, Inc.
NASDAQ:PGNY
Intrinsic Alpha fair value
Locked
Current Price
$36.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.